ANGLE plc is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca (LSE/STO/Nasdaq: AZN). This follows an earlier agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response (DDR) assay, announced on 24 April 2024.

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in First Quarter 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics andoffers the potential for long-term, ongoing business for the Company supportingclinical studies.

AR is a nuclear protein involved in cell growth and proliferation, cell cycle progression, protein synthesis, and cell death. The analysis of Parsortix® harvested CTCs using the Company's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up. There are more than 130 active, interventional oncology clinical studies in 30,000 participants, which include androgen receptor assessment, registered on clinicaltrials.gov.